Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.94 (market cap $12.58B), while Venture Global Inc. Class A common stock trades at $13.19 (market cap $33.23B). The key difference: Venture Global Inc. Class A common stock is far larger — about 2.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.2% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Venture Global Inc. Class A common stock for 0 Days on average.
| HALO | VG | |
|---|---|---|
Market Cap | $12.58B | $33.23B |
Volume | 2,179,278 | 12,625,066 |
Sector | Health | Energy |
52-Week High | $115.22 | $17.53 |
52-Week Low | $61.63 | $5.92 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.49B | $72.61B |
Dividend Yield | — | 1.2% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
